HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).

Abstract
Iron overload is considered to be associated with various complications in patients who undergo both allogeneic (allo) and autologous hematopoietic stem cell transplantation (HSCT). A total of 23 alloHSCT recipients who started deferasirox treatment due to hyperferritinemia (ferritin ≥1,000 ng/mL) were analyzed retrospectively. The demographic characteristics, data about deferasirox treatment, and history of phlebotomy were obtained from the patients' files. The reduction in posttreatment ferritin levels was found statistically significant compared with pretreatment ferritin levels in both def+phlebotomy and def+nonphlebotomy groups (p = 0.025 and 0.017, respectively). The liver enzymes, especially ALT and bilirubins, were significantly reduced after the treatment (p < 0.05). The deferasirox treatment reduced pretreatment ferritin levels below the level of 1,000 ng/mL in a median period of 94 days, and these data were found to be statistically significant (p < 0.05). The median treatment duration time with deferasirox was 94 days (72-122). The most common adverse effects were nausea and vomiting, which occurred in three of the patients (13%). In conclusion, our data suggest that oral deferasirox treatment may be used as a safe and effective alternative method for reducing iron overload in alloHSCT recipients, whether combined with or without phlebotomy.
AuthorsSerdar Sivgin, Bulent Eser, Sami Bahcebasi, Leylagul Kaynar, Fatih Kurnaz, Elmas Uzer, Cigdem Pala, Kemal Deniz, Ahmet Ozturk, Mustafa Cetin, Ali Unal
JournalAnnals of hematology (Ann Hematol) Vol. 91 Issue 5 Pg. 743-749 (May 2012) ISSN: 1432-0584 [Electronic] Germany
PMID22051904 (Publication Type: Journal Article)
Chemical References
  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Deferasirox
Topics
  • Adolescent
  • Adult
  • Benzoates (adverse effects, therapeutic use)
  • Deferasirox
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Iron Chelating Agents (adverse effects, therapeutic use)
  • Iron Overload (drug therapy, etiology, mortality)
  • Kidney (physiopathology)
  • Leukemia (complications, therapy)
  • Leukemia, Myeloid, Acute (complications, therapy)
  • Liver (pathology, physiopathology)
  • Male
  • Middle Aged
  • Phlebotomy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications, therapy)
  • Transplantation, Homologous
  • Triazoles (adverse effects, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: